Soleus Capital Management L.P. Buys 2,083,722 Shares of Grifols, S.A. (NASDAQ:GRFS)

Soleus Capital Management L.P. boosted its holdings in shares of Grifols, S.A. (NASDAQ:GRFS - Free Report) by 46.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 6,605,425 shares of the biotechnology company's stock after purchasing an additional 2,083,722 shares during the period. Grifols makes up 3.1% of Soleus Capital Management L.P.'s investment portfolio, making the stock its 6th largest holding. Soleus Capital Management L.P. owned about 0.96% of Grifols worth $49,144,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of GRFS. Tidal Investments LLC increased its position in Grifols by 49.3% in the 4th quarter. Tidal Investments LLC now owns 24,638 shares of the biotechnology company's stock valued at $183,000 after acquiring an additional 8,138 shares during the period. Quantinno Capital Management LP grew its stake in shares of Grifols by 22.7% in the 4th quarter. Quantinno Capital Management LP now owns 128,303 shares of the biotechnology company's stock valued at $955,000 after purchasing an additional 23,758 shares during the last quarter. Oasis Management Co Ltd. grew its stake in shares of Grifols by 19.8% in the 4th quarter. Oasis Management Co Ltd. now owns 1,157,607 shares of the biotechnology company's stock valued at $8,613,000 after purchasing an additional 191,137 shares during the last quarter. Janus Henderson Group PLC increased its holdings in shares of Grifols by 11.9% in the fourth quarter. Janus Henderson Group PLC now owns 3,045,260 shares of the biotechnology company's stock valued at $22,642,000 after purchasing an additional 324,869 shares during the period. Finally, Eisler Capital Management Ltd. purchased a new stake in shares of Grifols during the fourth quarter worth approximately $846,000.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on GRFS shares. Wall Street Zen upgraded shares of Grifols from a "hold" rating to a "buy" rating in a research report on Thursday, May 15th. Morgan Stanley initiated coverage on shares of Grifols in a research note on Wednesday, February 12th. They issued an "overweight" rating for the company.

Grifols Stock Performance

Shares of GRFS stock traded down $0.06 during trading hours on Thursday, reaching $8.13. 292,603 shares of the company's stock were exchanged, compared to its average volume of 1,160,427. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.26 and a quick ratio of 0.79. The company's 50 day moving average is $7.31 and its two-hundred day moving average is $7.62. The company has a market cap of $5.59 billion, a P/E ratio of 6.95 and a beta of 0.44. Grifols, S.A. has a 1 year low of $5.79 and a 1 year high of $9.96.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.